{"title": "OMC", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2009-05-01", "cleaned_text": "OMS-OMPI-OMC Promover el acceso a las tecnolog\u00edas y la innovaci\u00f3n en medicina: Intersecciones entre la salud p\u00fablica, la propiedad intelectual y el comercio Bibliograf\u00eda Abbott, F.M. y Van Puymbroeck, R.V. (2005), Compulsory Licensing for Public Health: A Guide Model Documents for Implementation of the Doha Declaration Paragraph 6 Decision, Washington, DC, Banco Mundial. Abbott, F.M. y Correa, C.M. (2007), World Trade Patented Medicines under the Amended 10(4): 921-87. (2010), \"Trade in Healthcare and as and Competition A Dual Challenge for Good Governance\", En: Arrowsmith, S. y Anderson, R.D. (eds.), The WTO Regime on Government Procurement: Challenge and Reform, Cambridge, Cambridge University Press, pp. 681-718. Attaran, A. (2004), \"How Do Patents of Mark-ups in the Pharmaceutical Pharmaceutical Policies and Interventions. R. Pogany, J. y International Perspective on Innovation, Competition and Policy, Aldershot, Edward Elgar. Banco Mundial (2005), A Guide to Competitive Vouchers in Health, Washington, DC, Banco Mundial. Banco Mundial (2009), \"Europe and Central Asia Health Insurance and Competition\", World Bank Report No. 44316-ECA. Banco Mundial (2011), \"Governance in the Health Sector: A Strategy for Performance\", Policy Ben-Ayre, et al. (2012), \"Integrative Oncology in the From \"Diffusion of New Drugs in the Post-TRIPS Era\", International Journal of the Economics the Needs of the Developing World, Washington, DC, BIO Ventures for Global Health. Blouin, C., Drager, N. y Smith, R., (eds.) (2006), International Trade in Health Services and the GATS: Current Issues and Debates, Washington, DC, Banco Mundial. Bregonje, M. (2005), \"Patents: A Unique Source for Scientific Industry?\", World Patent \"Cost Originator Brand Medicines to Generic Equivalents\", World Health Report Background Paper No. 35. Cameron A. et al. (2011), \"Differences in the Availability of Medicines for Chronic and Acute and Private Sectors of Developing Bulletin of Goldberg, P.K. y Effects of Global Patent Protection in Pharmaceuticals: A Case Study Quinolones in American Economic Review 96(5): 1477-1514. CIOMS (2002), Pautas \u00e9ticas internacionales para la investigaci\u00f3n biom\u00e9dica en seres humanos, Ginebra, Consejo de Organizaciones Internacionales de Ciencias M\u00e9dicas. Clift, C. (2010), \"Combating Counterfeit, Falsified and Substandard Medicines: Political the Pharmaceutical Industry\", Journal of Economic Literature 24(3): 1178-1217. Comisi\u00f3n Europea (2003), Vaccines Research Relief: Introduction of a New Scheme and Modification of State Aid N 802/99, Comisi\u00f3n Europea (2003) 1398. Comisi\u00f3n Europea (2009), Pharmaceutical Sector Inquiry: Final Report, Comisi\u00f3n Europea. Comisi\u00f3n Europea (2010), Reports on EU Customs Enforcement of Intellectual Property Rights: Results at the EU Border - 2010, Luxemburgo, Comisi\u00f3n Europea. Comisi\u00f3n Europea (2012), \"Medical Devices: European IP/12/119 of 9 February 2012. Commission on Health Research for Development (1990), Health Research: Essential Link to Equity in Development, Nueva York, Oxford University Press. Competition Bureau (2000), Intellectual Property Trade Marks and Allied Rights, 4th Edition, Reino Unido, Sweet and Maxwell. Correa, C.M. (2004), Implementation of the WTO General Council Decision on Paragraph 6 of the DOHA Declaration on the Trips Agreement and Public Health, Health Economics and Drugs Series No. 016, Ginebra, OMS. Correa, C.E. (2009), \"Case 2. The SARS Case: IP Fragmentation and Patent Pools\", Van Overwalle, G. (ed.), Gene Patents and Collaborative Licensing Models, Cambridge, Cambridge University Press, pp. 33-41. Creese, A., (2011), \"Working Paper 5: Sales Taxes Series on Pharmaceutical Pricing and Mulcahy, Innovation: New Estimates of EDCTP (2011), 2011 Annual Report, La Haya, Asociaci\u00f3n de Europa y los pa\u00edses en desarrollo para la realizaci\u00f3n de ensayos cl\u00ednicos. El Said, M.K. (2010), Public Health Related Trips-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region, Ginebra, OMS/ICTSD. EMA (2012), Access to Clinical-Trial Data and Transparency: Workshop Report, Agencia Europea de Medicamentos. Espin, J., Rovira, J., Olry de Labry, A., (2011), \"Working Paper Development: A Handbook, DC, Mundial, Fondo Mundial (2010a), Procurement and Supply Management to Writing PSM Plans. Fondo Mundial (2010b), Servicios de apoyo a las adquisiciones. Proceso de adquisiciones conjuntas voluntarias (VPP). Frost, L.J., y Reich, M.R. (2010), \"How Do Good Health Technologies Get to Poor People in Poor Countries\", Massachusetts, Harvard Center for Population and Development Studies. Ganslandt, y Maskus, Imports of Pharmaceutical Products: Evidence from the European Union,\" Journal of Health Economics 23(5): 1035-57. Garrido, M.V. et al. (2008), Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and WHO-Europe/European Definition of the Term \"Medical Device\", Global Harmonization Task Force document Schieber, G. (2006), Health Financing Revisited: A Practitioner's Guide, Washington, DC, Banco Mundial. Government India (2012), Guidelines on Similar Biologics: Regulatory Authorization Requirements for Marketing Authorization in India, Nueva Delhi, Government of India. Grabowski, H.G. y Kyle, M. (2007), \"Generic and Encourage Innovation for Neglected Diseases\", North Partnerships (PDPs): Lessons from Health Technologies for Neglected Diseases\", Department for International Development, Reino Unido. Greene, J. (2010), \"When Did Medicines Become Essential?\", Bulletin of the World Health Hawkins, L. (2011), \"Working Paper 4: Competition Series Helble, M. (2012), \"More Trade for Better Health? International Trade and Tariffs on Health Products\", WTO Staff Working Paper ERSD-2012-17. Hendriks, J. et al. (2011), \"An International Influenza Vaccines,\" Vaccine, 29(Suppl. 1): al. (2006), Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable Through the Courts?\", Lancet 368: 305-11. Hogerzeil, H.V. y World Medicines Situation: Access to Essential Medicines as Part of the Right to Health, Ginebra, OMS. Holloway, K. y Van Dijk, L. (2011), The World Medicines Situation: Rational Use of Medicines, Ginebra, OMS. ICTSD/UNCTAD/OMS (2007), Pautas para el examen de patentes farmac\u00e9uticas. Una perspectiva desde la salud p\u00fablica, Ginebra.. IFPMA (2011), The Pharmaceutical Industry and Global Health: Facts and Figures, Ginebra, IFPMA. IFPMA (2013), Discover Cures for with Neglected is Disrupting Itself,\" Harvard Business Review, October. Institute of Medicine (2012), \"Ensuring Safe Foods and Medical Products Through Stronger Regulatory Systems Abroad\", Report Brief, National Academy of Sciences. IPO Patent Thickets: An Overview, Newport, Intellectual Property Office. Kanavos, al. (2010), Impact of Health Technology Assessments: An International Comparison 2010\", Euro Observer 12(4): 1-7. Kaplan, W. y Laing, R. (2005), \"Local Production Pharmaceuticals: Industrial Policy and Access to Medicines\", HNP Discussion Paper, Washington, DC, Banco Mundial. Ker, U. (2012), \"Advance Market Commitment: Saving Lives Through Vaccine Delivery - UPDATE,\" Case Studies for Global Health. Khor, M. (2007), Series 10. King, Use of y Connor, C. (1998), Using Tax Relief to Support Public Health Goals, Partners for Reformplus. Krattiger, A. (2007a), et al. (eds.), Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, Oxford, MIHR and Davis, Krattiger, A. et al. (eds.), (2007b) Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, Oxford, Drugs: How Policy Affects Global Market Entry\", NBER Working Paper No. 11321. Levin, R. et al. (1987), \"Appropriating the Returns from Industrial Research and Development\", Brookings Papers on Economic Activity 3: of Pharmaceutical Research\", BioSocieties 6: 34-50. Liu, L. et al. (2012), \"Global, and National Causes of Child Mortality: An Updated Systematic Analysis for 2010 with Time Trends since 2000\", The Lancet 379(9832): 2151-61. Love, J. (2003), \"Evidence Regarding Research and Development Investments in Innovative and Non Innovative Medicines\", Consumer Management Science 32(2): 173-81. Masum, H. y Harris, R. (2011), Open Source for Neglected Disease: Magic Bullet or Mirage?, Washington, DC, Results for Development Institute. Mathers, C.D. et al. (2006), \"The Burden of Disease Results for 2001\", in Lopez, A.D. et al. (eds.), Global Burden of Disease and Risk Factors, Nueva York, Oxford University Press, pp. 45-240. Mathers, C.D. y Loncar, D. (2006), \"Projections of Global and Discovery to Invention. A Geneticist's View\", in Van Overwalle, G. (ed.), Gene Patents and Collaborative Licensing Models, Cambridge, Cambridge University Press, (2007), \"Open and Drugs: Characteristics of Their Use to Meet Public Health Goals\", HNP Discussion Paper, Washington, DC, Banco Mundial. Ministry of Health and Social Welfare (2008), Mapping of Partners and Financial Flows in the Medicines Supply System in Tanzan\u00eda, Dar es Salaam, Ministry of Health and Social Welfare. Mirza, Z. (2008), \"Thirty Years of Essential Medicines New Landscape of Neglected Disease Drug Development, The London School of Economics and Political Sciences. Moran, M. et al. (2012), Neglected Disease Research And Development: A Five Year Review, G-Finder Report 2012, Londres, Policy Cures. Morgan, S. et al. (2011), \"The Access to Medicines and Health Technologies, Arlington, Management Sciences for Health. M\u00fcller, A.C. y Pelletier, P. (en preparaci\u00f3n), \"Competition Policy and Government Procurement, Two Missing Links in the Debate on Public Health\", WTO Staff Working Paper. Munos, B. (2009), \"Lessons from 60 Years of Pharmaceutical Innovation,\" Nature Reviews Drug Discovery 8: 959-68. Murray, C.J.L. A.D. (eds.) (1996), The Global Burden of Disease, Cambridge, Harvard School of Public Health. Naciones Unidas (2011a), Declaraci\u00f3n Pol\u00edtica sobre el VIH/SIDA: intensificaci\u00f3n de nuestro esfuerzo para eliminar el VIH/SIDA, Informe de 2011 del Grupo de Tareas sobre el desfase en el logro de los Objetivos de Desarrollo del Milenio, Nueva York, Asamblea General de las Naciones Unidas. Naciones Unidas (2011b), Objetivo de Desarrollo del Milenio 8. La alianza mundial para el desarrollo: es hora de cumplir, Nueva York, Naciones Unidas. Naciones Unidas (2012), Los Objetivos de Desarrollo del Milenio: Informe de 2012, Nueva York, Naciones Unidas. NCD Alliance (2011), \"Access to Essential Medicines and Technologies for NCDs\", NCD Alliance et al. (2008), \"Medicines from Nature\", En: Chivian, E. y Bernstein, A. (eds.) Sustaining Life: How Human Health Depends on Biodiversity, Oxford, Oxford University Press. Ni\u00ebns, L. et al. (2010), the Impoverishing Subjects Protection and Inclusion Issues, National Institutes Health. (2009), \"Placing FDA's Priority Review Vouchers\", (2007), of Antiretroviral Drug Costs in Brazil in the Context of Free Access to AIDS Treatment\", PLoS 4(11): e305. Medicine 7(6): e1000293. Obrist, B. et to Health Care in Contexts of Livelihood Insecurity: A Framework for Analysis and Governance and It, Par\u00eds, OCDE. OCDE (2008), Pharmaceutical Pricing Policies in a Global Market, Par\u00eds, OCDE. OCDE (2011), OECD Science, Technology and Industry Scoreboard 2011: Innovation and Growth in Knowledge Economies, Par\u00eds, OCDE. OECS (2001), Pharmaceutical Procurement Service Annual Report 2001, Saint Lucia, Organisation of Eastern Caribbean States. Office of Technology Assessment (1993), Pharmaceutical R&D: Costs, Risks and Rewards, Washington, Laing, R. \"Pharmaceutical Tariffs: What is Their Effect on Protection of Local Industry and Revenue Generation?\", prepared for the Commission on Intellectual Property Rights, Innovation and Public Health, OMS. Olson, S. A. (2011), Establishing Precompetitive Drugs: Background Note Prepared by Jayashree Watal, consultora de la Secretar\u00eda de la OMC, Ginebra, OMC. OMC (2009), \"Services Liberalization from a WTO/GATS Perspectives: In Search of Volunteers\", WTO Staff Working Paper ERSD-2009-05. OMC (2010), Examen anual de la Decisi\u00f3n sobre la aplicaci\u00f3n del p\u00e1rrafo 6 de la Declaraci\u00f3n de Doha relativa al Acuerdo sobre los ADPIC y la Salud P\u00fablica, Informe al Consejo General, Ginebra, OMC. OMC (2011), Informe sobre el comercio mundial 2011, Ginebra, OMC. OMPI (2001), Conocimientos tradicionales: necesidades y expectativas en materia de propiedad intelectual. Informe relativo a las misiones exploratorias sobre propiedad intelectual y conocimientos tradicionales (1998-1999), Ginebra, OMPI. OMPI (2008), SCP/12/3 Rev.2, Anexo III Comentarios de los Miembros y Observadores del SCP acerca del Informe sobre el sistema internacional de patentes, Ginebra, OMPI. OMPI (2009), The Economics of Intellectual Property, Ginebra, OMPI. OMPI (2010), OMPI (2010), Gu\u00edas para bases de datos tecnol\u00f3gicas, Ginebra, OMPI. OMPI (2011a), Informe de 2011 sobre la propiedad intelectual en el mundo, Ginebra, OMPI. OMPI (2011b), WIPO Survey on Patenting Strategies in 2009 and 2010, Ginebra, OMPI. OMPI (2011c), Patent Search Report on Pandemic Influenza Preparedness and Patent Applications, Ginebra, OMPI. OMPI (2012), Rese\u00f1a anual del PCT 2012: El Sistema Internacional de Patentes, Ginebra, OMPI. OMS (2000a), Informe sobre la Salud en el Mundo 2000: Mejorar el desempe\u00f1o de los sistemas de salud, Ginebra, OMS. OMS (2000b), Pautas generales para las metodolog\u00edas de investigaci\u00f3n y evaluaci\u00f3n de la medicina tradicional, Ginebra, OMS. OOMS (2001a), Macroeconom\u00eda y salud: Invertir en salud en pro del desarrollo econ\u00f3mico, Ginebra, OMS. OMS (2001b), Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review, Ginebra, OMS. OMS (2001c), \"Adquisici\u00f3n de los medicamentos: principios de una actuaci\u00f3n correcta\", Bolet\u00edn de Medicamentos Esenciales No. 30, Ginebra, OMS. OMS (2001d), C\u00f3mo desarrollar y aplicar una pol\u00edtica farmac\u00e9utica nacional, Ginebra, OMS. OMS (2002a), \"The Selection and Use of Essential Medicines: Report of the WHO Expert Committee,\" WHO Technical Report Series 914. OMS (2002b), Estrategia de la OMS sobre medicina tradicional 2002-2005, Ginebra, OMS. OMS (2003a), Medical Device Regulations: Global Overview and Guiding Principles, Ginebra, OMS. OMS (2003b), \" C\u00f3mo desarrollar y aplicar una pol\u00edtica farmac\u00e9utica nacional\", Perspectivas pol\u00edticas de la OMS sobre medicamentos, No. 06, enero de 2003. OMS (2004a), WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, Ginebra, OMS. OMS (2004b), Priority Medicines for Europe and the World, Ginebra, OMS. OMS (2004c), \"Acceso equitativo a los medicamentos esenciales: Un marco para la acci\u00f3n colectiva\", Perspectivas pol\u00edticas de la OMS sobre medicamentos, No. 8, marzo de 2004. OMS (2005a), Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies, Health Economics and Drugs TCM Series No. 18. OMS (2005b), National Policy on Traditional Medicine and Regulation of Herbal Medicines: Report of a WHO Global Survey, Ginebra, OMS. OMS (2006a), Fortieth Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series 937. OMS (2006b), Salud P\u00fablica, innovaci\u00f3n y derechos de propiedad intelectual: Informe de la Comisi\u00f3n de Derechos de Propiedad Intelectual, Innovaci\u00f3n y Salud P\u00fablica, Ginebra, OMS. OMS (2007), Everybody's Business: Strengthening Health Systems to Improve Health Outcomes - WHO's Framework for Action, Ginebra, OMS. OMS (2008), The Global Burden of Disease: 2004 Update, Ginebra, OMS OMS (2009), Global Health Risks: Mortality and Burden of Disease Attributable Ginebra, OMS. OMS (2010a), Dispositivos m\u00e9dicos: La gesti\u00f3n de la discordancia. Un resultado del Proyecto sobre Dispositivos M\u00e9dicos Prioritarios, Ginebra, OMS. OMS (2010b), Global Status Report on Noncommunicable Diseases 2010, Ginebra, OMS. OMS (2010c), Assessment in 26 Assessment Ginebra, to Prevent Corruption in the Pharmaceutical Sector\", World Health Report (2010) Background Paper 25 OMS (2010e), \"New Progress and Guidance on Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases, Ginebra, OMS. OMS (2010g), Coordinaci\u00f3n y financiaci\u00f3n de la investigaci\u00f3n y el desarrollo: Informe del Grupo de Expertos, Ginebra, OMS. OMS (2010h), Informe sobre la salud en el mundo. Financiaci\u00f3n de los sistemas de salud: el camino hacia la cobertura universal, Ginebra, OMS. OMS (2011a), Estad\u00edsticas sanitarias mundiales, Ginebra, OMS. OMS (2011b), Survey of the Quality of Selected Antimalarial Medicines Circulating OMS OMS (2011c), Increasing Access to Vaccines Through Technology Transfer and Local Production, Ginebra, OMS. OMS (2011d), WHO Model List of Essential Medicines, 17th list, Ginebra, OMS. OMS (2011e), Pharmaceutical Production and Related Technology Transfer, Ginebra, OMS OMS (2011f), WHO Model List of Essential Medicines for Children, 3rd list, Ginebra, OMS. OMS (2011g), Local Production for Access to Medical Products: Developing a Framework to Improve Public Health, Ginebra, OMS. OMS (2011h), Funci\u00f3n de la OMS en la prevenci\u00f3n y el control de productos m\u00e9dicos deficientes en cuanto a su calidad, seguridad y eficacia tales como los de calidad subest\u00e1ndar, espurios, de etiquetado enga\u00f1oso, falsificados o de imitaci\u00f3n, Ginebra, OMS (A/SSFFC/WG/3 Rev.1). Puede consultarse en: http://apps.who.int/gb/ssffc/s/ssffc_wg1.html. OMS (2012a), Investigaci\u00f3n y desarrollo para atender las necesidades sanitarias de los pa\u00edses en desarrollo: fortalecimiento de la financiaci\u00f3n y coordinaci\u00f3n mundiales, Ginebra, OMS. OMS (2012b), The Strategic Use of Antiretrovirals to Help End the HIV Epidemic, Ginebra, OMS. OMS (2012c), Estad\u00edsticas Sanitarias Mundiales 2012, Ginebra, OMS. OMS/HAI (2008), Measuring Medicine Prices, Availability, Affordability and Price Components, Ginebra, OMS, y \u00c1msterdam, HAI. OMS y OMC (2002), Los Acuerdos de la OMC y la salud p\u00fablica: un estudio conjunto de la OMS y la Secretar\u00eda de la OMC OMS y ONUSIDA (2002), Accelerating Access Initiative: Widening Access to Care and Support for People Living with HIV/AIDS, Ginebra, OMS/ONUSIDA. OMS, ONUSIDA y UNICEF (2011), Global HIV/AIDS and Health Sector Progress Towards Universal Access: Progress Report 2011, Ginebra, OMS. OMS y UNICEF (2006), Essential Medicines for Children Expert Consultation Report of the Joint WHO-UNICEF Consultation on Essential Medicines for Children, Ginebra, OMS. OMS, UNICEF y Banco Mundial (2009), Vacunas e inmunizaci\u00f3n: situaci\u00f3n mundial, Ginebra, OMS. ONUSIDA (2012), Hoja Informativa Mundial, D\u00eda Mundial del Sida, Ginebra, ONUSIDA. ONUSIDA, OMS, PNUD (2011), \"Aprovechar las flexibilidades de los ADPIC para mejorar el acceso al tratamiento del VIH.\" Nota informativa. Oxfam/MSF (2010), Giving Developing Countries the Best Vaccine Access and R&D, Ginebra, MSF. S. Ginebra, OMS. Drug Discovery Lifts Lid on Drug Data Secrets\", 16 July 2012. Ridley, D., Grabowski, of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners\", Workshop on Access and Benefit Sharing, Bonn, 26 May 2008. Robertson, J. et al. (2009), \"What Essential Medicines for Children are on the Shelf?\", Bulletin of the World Health Organization 87(3): 231-7. Roger, S.D. y Goldsmith, D. (2008), \"Biosimilars: It's Not as Simple as Cost et al. (2012), \"Securing the Public Good of Health Research and Development for Developing Countries\", Bulletin of the World Health Organization 90(5): 398-400. G. (2010), \"Bio-Business in Current Science 98(12): 1575-78. Scheib, J. y Witherell, B. (2011), \"The INTA Scherer, to Patented Medicines in Developing Nations\", Journal of International Lerner, y Stern, S. (eds.), Innovation Policy and the Economy, Cambridge, MIT Press, pp. 119-50. J. et A.J. et al. (2011), \"The Role of Public-Sector Research in the Discovery of Drugs and Vaccines\", New England Journal of Medicine 364(6): 535-41. 't Hoen, E.F.M. (2009), The Publishers. Taubman, A. (2010), \"A Typology Economic Impact of the Patent System: A Study of the British Experience, Cambridge, Cambridge Press University. Temin, P. (1979), \"Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry\", The Bell Journal of Economics 10(2): 429-46. Tempest, B. (2011), \"The Structural Mortality Report 2012: Estimates the UN Inter-agency Group Child Mortality Estimation, Nueva York, UNICEF. UNITAID (2009), \"UNITAID and the Clinton HIV/AIDS Initiative Announce New Price Reductions for Key Drugs\", UNITAID HIV/AIDS: Scaling Treatment Up, Pushing Prices Down, Ginebra, US Department of Justice/Federal Trade Antitrust Guidelines for the Licensing of Intellectual Property. USCBO (2006), Research and Development in the Pharmaceutical Industry, Congress of the United States, Congressional Budget Office. Uzuner, H. et al. (2012), \"Traditional Chinese Medicine Research in the Post-Genomic Era: Good Challenges and (2012), \"Intellectual Property Provisions in Regional Trade Agreements\", WTO Staff Working paper ERSD-2012-21. Van den Ham, R., Bero, L. y Laing, R. (2011), The World Medicines Situation 2011: Selection of Essential Medicines, Ginebra, Patent Law: The Case of Myriad\", WIPO Magazine 4: 8-9. Wagner, A. et al. (2011), \"Access to Care and Medicines, Burden of Health Care Expenditures, and Risk Protection: Policy 100(2-3): B., International AIDS Society 13: 35. Widdus, R. y White, K. (2004), Combating Diseases Associated with Poverty: Financing Strategies Potential Ginebra, OMS. Yadav, P. (2010), Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action\", A study conducted for the UK Department for International Development (DFID). Yamane, H. (2011), Interpreting TRIPS: Globalisation of Intellectual and Access to Medicines, Oxford and Portland, Oregon, Hart Publishing. "}